2026 Scott J. Rodig: Medicine Researcher – H-Index, Publications & Awards

Discipline name	D-Index	World Ranking	Current World Ranking	National Ranking	Current National Ranking	Publications	Citations
Medicine	132	2283	2125	1290	1182	577	81287

Overview

Scott J. Rodig is affiliated with Harvard University in the United States. Their research primarily spans the fields of Medicine and Biochemistry, Genetics, and Molecular Biology, with a specific focus on oncology and related biomedical disciplines.

The scientist has a substantial publication record in oncology, with notable subfields of study including Oncology, Molecular Biology, Immunology, Pulmonary and Respiratory Medicine, and Cancer Research.

Main topics of their work reflect these interests and include:

Cancer Immunotherapy and Biomarkers
Cancer Genomics and Diagnostics
CAR-T cell therapy research
Single-cell and spatial transcriptomics
Lung Cancer Treatments and Mutations
Immune Cell Function and Interaction
Immunotherapy and Immune Responses

Scott J. Rodig's frequent co-authors are Kathleen L. Pfaff, Mark M. Awad, Joao V. Alessi, Jason L. Weirather, and Biagio Ricciuti, reflecting collaborative work within these research domains.

Their recent papers include the following:

"Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma," 2021, Nature Medicine
"Expansion sequencing: Spatially precise in situ transcriptomics in intact biological systems," 2021, Science
"Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels," 2022, JAMA Oncology
"Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer," 2020, Nature Communications
"Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity," 2020, Journal of Clinical Oncology

The scientist has published extensively in multiple venues, with the most frequent being:

Journal of Clinical Oncology
bioRxiv (Cold Spring Harbor Laboratory)
Cancer Research
Blood
Cold Spring Harbor Protocols

Scott J. Rodig's research contributions focus on the molecular and immunological underpinnings of cancer, including therapeutic approaches such as CAR-T cell therapy and immune checkpoint blockade. Their work integrates clinical insights with molecular genomics and spatial transcriptomics techniques.

Best Publications

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

Stephen M. Ansell;Alexander M. Lesokhin;Alexander M. Lesokhin;Ivan Borrello;Ahmad Halwani

4020
Citations
An immunogenic personal neoantigen vaccine for patients with melanoma

Patrick A. Ott;Zhuting Hu;Derin B. Keskin;Derin B. Keskin;Sachet A. Shukla;Sachet A. Shukla

2980
Citations
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK

Alice T. Shaw;Beow Y. Yeap;Mari Mino-Kenudson;Subba R. Digumarthy

2340
Citations
Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway

Marco A Meraz;Marco A Meraz;J.Michael White;Kathleen C.F Sheehan;Erika A Bach

2059
Citations
Comprehensive analyses of tumor immunity: implications for cancer immunotherapy

Bo Li;Eric Severson;Eric Severson;Jean Christophe Pignon;Haoquan Zhao

2019
Citations
Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade.

Brian C. Miller;Debattama R. Sen;Debattama R. Sen;Rose Al Abosy;Rose Al Abosy;Kevin Bi;Kevin Bi

1949
Citations
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes

Bjoern Chapuy;Chip Stewart;Andrew J Dunford;Jaegil Kim

1919
Citations
Adaptive immunity maintains occult cancer in an equilibrium state

Catherine M. Koebel;William Vermi;William Vermi;Jeremy B. Swann;Jeremy B. Swann;Nadeen Zerafa

1770
Citations
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.

Shohei Koyama;Esra A. Akbay;Yvonne Y. Li;Grit S. Herter-Sprie

1601
Citations
Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma

Michael R. Green;Stefano Monti;Scott J. Rodig;Przemyslaw Juszczynski

1561
Citations
MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia

Steven P. Treon;Lian Xu;Guang Yang;Yangsheng Zhou

1415
Citations
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

Derin B. Keskin;Annabelle J. Anandappa;Jing Sun;Itay Tirosh

1363
Citations
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors

Esra A. Akbay;Esra A. Akbay;Shohei Koyama;Julian Carretero;Abigail Altabef;Abigail Altabef

1347
Citations
Nivolumab in patients with relapsed or refractory hematologic malignancy: Preliminary results of a phase ib study

Alexander M. Lesokhin;Alexander M. Lesokhin;Stephen M. Ansell;Philippe Armand;Emma C. Scott

1082
Citations
Disruption of the Jak1 Gene Demonstrates Obligatory and Nonredundant Roles of the Jaks in Cytokine-Induced Biologic Responses

Scott J Rodig;Marco A Meraz;J.Michael White;Pat A Lampe

1062
Citations
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

Anas Younes;Armando Santoro;Margaret Shipp;Pier Luigi Zinzani

984
Citations
Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia

Steven P. Treon;Christina K. Tripsas;Kirsten Meid;Diane Warren

969
Citations
Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

James E. Butrynski;David R. D’Adamo;Jason L. Hornick;Paola Dal Cin

925
Citations
PD-L1 EXPRESSION IS CHARACTERISTIC OF A SUBSET OF AGGRESSIVE B-CELL LYMPHOMAS AND VIRUS-ASSOCIATED MALIGNANCIES

Benjamin J. Chen;Bjoern Chapuy;Jing Ouyang;Heather H. Sun

922
Citations
Tet1 and Tet2 Regulate 5-Hydroxymethylcytosine Production and Cell Lineage Specification in Mouse Embryonic Stem Cells

Kian Peng Koh;Akiko Yabuuchi;Sridhar Rao;Yun Huang

891
Citations

Frequent Co-Authors

Margaret A. Shipp Harvard University

Donna Neuberg Harvard University

Philippe Armand Harvard University

Gordon J. Freeman Harvard University

F. Stephen Hodi Harvard University

Jeffery L. Kutok Epizyme (United States)

Gad Getz Broad Institute

Geoffrey I. Shapiro Harvard University

Andrew L. Kung Memorial Sloan Kettering Cancer Center

Catherine J. Wu Harvard University

External Links

Personal website of Scott J. Rodig

If you think any of the details on this page are incorrect, let us know.

Related Online Degrees & Career Pathways

Pursuing Medicine in the USA can open doors to a variety of related degrees and health career options—many of which can now be accessed through flexible online programs. Students interested in improving community health and wellness might consider exploring the best online nutrition programs for specialized study in nutritional science, dietetics, or food policy.

For those drawn to healthcare leadership or administration, knowing how to evaluate programs is essential. Understanding how to evaluate healthcare administration degree programs helps ensure your chosen path meets accredited standards, which can be crucial for career advancement.

Nursing professionals who wish to advance without the challenge of additional clinical hours may wish to consider the best online rn to bsn programs without clinical requirements. These programs are ideal for working nurses balancing education and employment.

For advanced practice nurses looking to quickly move into leadership or clinical specialist roles, the fastest online dnp programs allow for an expedited path to the highest level of nursing education.